{
 "cells": [
  {
   "metadata": {},
   "cell_type": "markdown",
   "source": [
    "# Scrape Information from the FDA\n",
    "\n",
    "The openFDA contains information to obtain data from their JSON file (see tutorial [here](01_Fetch_Data.ipynb)). However, the information is updated regularly. During testing, it was seen that the information in that data extended up to 2020. As a workaround, drug_nme includes additional methods to extract information from the FDA from several sources, which will be demoed below. "
   ]
  },
  {
   "metadata": {},
   "cell_type": "markdown",
   "source": "### Import modules"
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-07-23T09:43:41.941128Z",
     "start_time": "2024-07-23T09:43:41.866298Z"
    }
   },
   "cell_type": "code",
   "source": [
    "import pandas as pd\n",
    "from drug_nme import FDAScraper"
   ],
   "outputs": [],
   "execution_count": 1
  },
  {
   "metadata": {},
   "cell_type": "markdown",
   "source": [
    "### Initialize the FDAScrapper() class\n",
    "\n",
    "The FDASCrapper() class will need to be initialized. This class can take several parameters. \n",
    "- url: the url to a specific site. By default, it will point to the [NME Drug and New Biologic Approvals](https://www.fda.gov/drugs/nda-and-bla-approvals/new-molecular-entity-nme-drug-and-new-biologic-approvals) page. \n",
    "- compilation_link: A link to the page containing the [Compilation of CDER NME Drug and New Biologic Approvals](https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals). \n",
    "- latest_link: A link to the page containing the [Novel Drug Approvals at FDA](https://www.fda.gov/drugs/development-approval-process-drugs/novel-drug-approvals-fda).\n",
    "\n",
    "By default, these are already set to the specific web addresses. However, if there are issues, users can try to use different sites. They can be set to the paramaters manually.  "
   ]
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-07-23T09:43:41.943190Z",
     "start_time": "2024-07-23T09:43:41.941776Z"
    }
   },
   "cell_type": "code",
   "source": "scrape = FDAScraper()",
   "outputs": [],
   "execution_count": 2
  },
  {
   "metadata": {},
   "cell_type": "markdown",
   "source": [
    "### Get NMEs From PDF Reports\n",
    "\n",
    "The FDA curates reports of approval by [calendar year](https://www.fda.gov/drugs/nda-and-bla-approvals/new-molecular-entity-nme-drug-and-new-biologic-approvals). The **get.pdf_links()** method will extract links to the PDFs. \n",
    "\n",
    "This will result in a dictionary containing the year and a link to the corresponding PDF report. This can be viewed by clicking or copy and pasting the link to the browser.  The links are also used to set the instance variable. Thus, it is not necessary to set the **get_pdf_links()** to a variable.\n",
    "\n",
    "**NOTE:** Currently, the FDA curates reports from 2015-2023. There are additional reports available for 1999-2014, however it is listed under the FDA Archive link. Extraction there can be difficult. A workaround will be demoed further below.    "
   ]
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-07-23T09:43:42.065706Z",
     "start_time": "2024-07-23T09:43:41.944475Z"
    }
   },
   "cell_type": "code",
   "source": [
    "# set to variable to demo the output\n",
    "links = scrape.get_pdf_links()\n",
    "links"
   ],
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'2023': 'https://www.fda.gov/media/177083/download?attachment',\n",
       " '2022': 'https://www.fda.gov/media/165828/download?attachment',\n",
       " '2021': 'https://www.fda.gov/media/158152/download?attachment',\n",
       " '2020': 'https://www.fda.gov/media/147400/download?attachment',\n",
       " '2019': 'https://www.fda.gov/media/147414/download?attachment',\n",
       " '2018': 'https://www.fda.gov/media/124809/download?attachment',\n",
       " '2017': 'https://www.fda.gov/media/110746/download',\n",
       " '2016': 'https://www.fda.gov/media/102967/download',\n",
       " '2015': 'https://www.fda.gov/media/93424/download'}"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "execution_count": 3
  },
  {
   "metadata": {},
   "cell_type": "markdown",
   "source": [
    "### Extract Table From PDF Report\n",
    "\n",
    "The above **get_pdf_links** method sets the instance variable in the FDAScrapper class. This can the nbe used to extract the table from the PDF file using the **extract_table()**. "
   ]
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-07-23T09:43:42.976114Z",
     "start_time": "2024-07-23T09:43:42.066523Z"
    }
   },
   "cell_type": "code",
   "source": [
    "year_2023 = scrape.extract_table(year='2023')\n",
    "year_2023"
   ],
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0  APPLICATION NUMBER                                PROPRIETARY NAME  \\\n",
       "1          NDA 214373                                       BRENZAVVY   \n",
       "2          NDA 216059                                        JAYPIRCA   \n",
       "3          NDA 217639                                         ORSERDU   \n",
       "4          NDA 216951                                       JESDUVROQ   \n",
       "5          NDA 216403                                        FILSPARI   \n",
       "6          NDA 216718                                       SKYCLARYS   \n",
       "7          NDA 216386                                        ZAVZPRET   \n",
       "8          NDA 217026                                          DAYBUE   \n",
       "9          NDA 217417                                         REZZAYO   \n",
       "10         NDA 217759                                          JOENJA   \n",
       "11         NDA 215887                                         QALSODY   \n",
       "12         NDA 216578                                          VEOZAH   \n",
       "13         NDA 216675                                           MIEBO   \n",
       "14         NDA 216974                                         XACDURO   \n",
       "15         NDA 216023                                         POSLUMA   \n",
       "16         NDA 217188                                        PAXLOVID   \n",
       "17         NDA 216203                                          INPEFA   \n",
       "18         NDA 215830                                         LITFULO   \n",
       "19         NDA 216993                                        VANFLYTA   \n",
       "20         NDA 217603                                          XDEMVY   \n",
       "21         NDA 217225                                         IZERVAY   \n",
       "22         NDA 217369                                        ZURZUVAE   \n",
       "23         NDA 215559                                         SOHONOS   \n",
       "24         NDA 217159                                         APHEXDA   \n",
       "25         NDA 216873                                         OJJAARA   \n",
       "26         NDA 021164                                           EXXUA   \n",
       "27         NDA 215842                                        RIVFLOZA   \n",
       "28         NDA 216956                           VELSIPITY (ETRASIMOD)   \n",
       "29         NDA 216834                           ZILBRYSQ (ZILUCOPLAN)   \n",
       "30         NDA 215239                            AGAMREE (VAMOROLONE)   \n",
       "31         NDA 217564                         FRUZAQLA (FRUQUINTINIB)   \n",
       "32         NDA 214520  TAUROLIDINE AND HEPARIN CATHETER LOCK SOLUTION   \n",
       "33         NDA 218213                                         AUGTYRO   \n",
       "34         NDA 218197                                          TRUQAP   \n",
       "35         NDA 217677                                         OGSIVEO   \n",
       "36         NDA 218276                                        FABHALTA   \n",
       "37         NDA 215064                                        FILSUVEZ   \n",
       "38         NDA 217388                                          WAINUA   \n",
       "41         BLA 761269                        LEQEMBI (LECANEMAB-IRMB)   \n",
       "42         BLA 761278                                         LAMZEDE   \n",
       "43         BLA 761334                                           ZYNYZ   \n",
       "44         BLA 761161                                        ELFABRIO   \n",
       "45         BLA 761324                                         EPKINLY   \n",
       "46         BLA 761309                                         COLUMVI   \n",
       "47         BLA 761286                                        RYSTIGGO   \n",
       "48         BLA 761184                        NGENLA (SOMATROGON-GHLA)   \n",
       "49         BLA 761328                                       BEYFORTUS   \n",
       "50         BLA 761342                                          TALVEY   \n",
       "51         BLA 761345                                        ELREXFIO   \n",
       "52         BLA 761339                                          VEOPOZ   \n",
       "53         BLA 761204                                       POMBILITI   \n",
       "54         BLA 761151                                         BIMZELX   \n",
       "55         BLA 761279                                           OMVOH   \n",
       "56         BLA 761240                                        LOQTORZI   \n",
       "57         BLA 761134                                        RYZNEUTA   \n",
       "\n",
       "0                                    ESTABLISHED NAME  \\\n",
       "1                                       BEXAGLIFLOZIN   \n",
       "2                                       PIRTOBRUTINIB   \n",
       "3                                         ELACESTRANT   \n",
       "4                                         DAPRODUSTAT   \n",
       "5                                          SPARSENTAN   \n",
       "6                                       OMAVELOXOLONE   \n",
       "7                                          ZAVEGEPANT   \n",
       "8                                         TROFINETIDE   \n",
       "9                                          REZAFUNGIN   \n",
       "10                               LENIOLISIB PHOSPHATE   \n",
       "11                                           TOFERSEN   \n",
       "12                                       FEZOLINETANT   \n",
       "13                               PERFLUOROHEXYLOCTANE   \n",
       "14  SULBACTAM FOR INJECTION; DURLOBACTAM FOR INJEC...   \n",
       "15                                 FLOTUFOLASTAT F 18   \n",
       "16                         NIRMATRELVIR AND RITONAVIR   \n",
       "17                                      SOTAGLIFLOZIN   \n",
       "18                                       RITLECITINIB   \n",
       "19                                        QUIZARTINIB   \n",
       "20                                          LOTILANER   \n",
       "21                                 AVACINCAPTAD PEGOL   \n",
       "22                                         ZURANOLONE   \n",
       "23                                       PALOVAROTENE   \n",
       "24                                      MOTIXAFORTIDE   \n",
       "25                                        MOMELOTINIB   \n",
       "26                                           GEPIRONE   \n",
       "27                                          NEDOSIRAN   \n",
       "28                                          ETRASIMOD   \n",
       "29                                         ZILUCOPLAN   \n",
       "30                                         VAMOROLONE   \n",
       "31                                       FRUQUINTINIB   \n",
       "32    TAUROLIDINE AND HEPARIN) CATHETER LOCK SOLUTION   \n",
       "33                                      REPOTRECTINIB   \n",
       "34                                       CAPIVASERTIB   \n",
       "35                                       NIROGACESTAT   \n",
       "36                                          IPTACOPAN   \n",
       "37                                  BIRCH TRITERPENES   \n",
       "38                                        EPLONTERSEN   \n",
       "41                                    LECANEMAB-IRMB)   \n",
       "42                                VELMANASE ALFA-TYCV   \n",
       "43                                  RETIFANLIMAB-DLWR   \n",
       "44                         PEGUNIGALSIDASE ALFA- IWXJ   \n",
       "45                                   EPCORITAMAB-BYSP   \n",
       "46                                   GLOFITAMAB-GXBM)   \n",
       "47                               ROZANOLIXIZUMAB-NOLI   \n",
       "48                                    SOMATROGON-GHLA   \n",
       "49                                    NIRSEVIMAB-ALIP   \n",
       "50                                   TALQUETAMAB-TGVS   \n",
       "51                                   ELRANATAMAB-BCMM   \n",
       "52                                     POZELIMAB-BBFG   \n",
       "53                         CIPAGLUCOSIDASE ALFA- ATGA   \n",
       "54                                        BIMEKIZUMAB   \n",
       "55                                   MIRIKIZUMAB-MRKZ   \n",
       "56                                   TORIPALIMAB-TPZI   \n",
       "57                       EFBEMALENOGRASTIM ALFA-VUXW)   \n",
       "\n",
       "0                                           APPLICANT REVIEW CLASSIFICATION  \\\n",
       "1                                     THERACOSBIO LLC                     S   \n",
       "2                                   LOXO ONCOLOGY INC                   P,O   \n",
       "3                           STEMLINE THERAPEUTICS INC                     P   \n",
       "4   GLAXOSMITHKLINE INTELLECTUAL PROPERTY NO 2 LTD...                     S   \n",
       "5                            TRAVERE THERAPEUTICS INC                   P,O   \n",
       "6                           REATA PHARMACEUTICALS INC                   P,O   \n",
       "7                                          PFIZER INC                     S   \n",
       "8                          ACADIA PHARMACEUTICALS INC                   P,O   \n",
       "9                             CIDARA THERAPEUTICS INC                   P,O   \n",
       "10                           PHARMING TECHNOLOGIES BV                   P,O   \n",
       "11                                      BIOGEN MA INC                   P,O   \n",
       "12                             ASTELLAS PHARMA US INC                     P   \n",
       "13                                BAUSCH AND LOMB INC                     S   \n",
       "14                           ENTASIS THERAPEUTICS INC                     P   \n",
       "15                         BLUE EARTH DIAGNOSTICS LTD                     S   \n",
       "16                                         PFIZER INC                     P   \n",
       "17                        LEXICON PHARMACEUTICALS INC                     S   \n",
       "18                                         PFIZER INC                     S   \n",
       "19                                 DAIICHI SANKYO INC                   P,O   \n",
       "20                         TARSUS PHARMACEUTICALS INC                     S   \n",
       "21                                     IVERIC BIO INC                     P   \n",
       "22                              SAGE THERAPEUTICS INC                     P   \n",
       "23                       IPSEN BIOPHARMACEUTICALS INC                   P,O   \n",
       "24                                      BIOLINERX LTD                   S,O   \n",
       "25                                GLAXOSMITHKLINE LLC                   S,O   \n",
       "26                   FABRE KRAMER PHARMACEUTICALS INC                     S   \n",
       "27                                   NOVO NORDISK INC                   S,O   \n",
       "28                                         PFIZER INC                     S   \n",
       "29                                            UCB INC                   S,O   \n",
       "30                       CATALYST PHARMACEUTICALS INC                   S,O   \n",
       "31                     TAKEDA PHARMACEUTICALS USA INC                     P   \n",
       "32                                       CORMEDIX INC                     P   \n",
       "33                            BRISTOL MYERS SQUIBB CO                   P,O   \n",
       "34                     ASTRAZENECA PHARMACEUTICALS LP                     P   \n",
       "35                       SPRINGWORKS THERAPEUTICS INC                   P,O   \n",
       "36                      NOVARTIS PHARMACEUTICALS CORP                   P,O   \n",
       "37                            CHIESI FARMACEUTICI SPA                   P,O   \n",
       "38                                     ASTRAZENECA AB                   S,O   \n",
       "41                                EISAI, INCORPORATED                     P   \n",
       "42                         CHIESI FARMACEUTICI S.P.A.                   P,O   \n",
       "43                                 INCYTE CORPORATION                   P,O   \n",
       "44                         CHIESI FARMACEUTICI S.P.A.                     P   \n",
       "45                                    GENMAB US, INC.                     P   \n",
       "46                                    GENENTECH, INC.                     P   \n",
       "47                                          UCB, INC.                   P,O   \n",
       "48                     PFIZER IRELAND PHARMACEUTICALS                   S,O   \n",
       "49                                     ASTRAZENECA AB                     S   \n",
       "50                              JANSSEN BIOTECH, INC.                   P,O   \n",
       "51                                        PFIZER INC.                   P,O   \n",
       "52                    REGENERON PHARMACEUTICALS, INC.                   P,O   \n",
       "53                        AMICUS THERAPEUTICS US, LLC                     S   \n",
       "54                                          UCB, INC.                     S   \n",
       "55                              ELI LILLY AND COMPANY                   S,O   \n",
       "56                          COHERUS BIOSCIENCES, INC.                   P,O   \n",
       "57            EVIVE BIOTECHNOLOGY SINGAPORE PTE. LTD.                     S   \n",
       "\n",
       "0  APPROVAL DATE                                         INDICATION  \n",
       "1      1/20/2023  ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEM...  \n",
       "2      1/27/2023  FOR THE TREATMENT OF ADULT PATIENTS WITH RELAP...  \n",
       "3      1/27/2023  FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN OR A...  \n",
       "4       2/1/2023  FOR THE TREATMENT OF ANEMIA DUE TO CHRONIC KID...  \n",
       "5      2/17/2023  TO REDUCE PROTEINURIA IN ADULTS WITH PRIMARY I...  \n",
       "6      2/28/2023  FOR THE TREATMENT OF FRIEDREICH'S ATAXIA IN AD...  \n",
       "7       3/9/2023  ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AU...  \n",
       "8      3/10/2023  FOR THE TREATMENT OF RETT SYNDROME IN ADULTS A...  \n",
       "9      3/22/2023  FOR THE TREATMENT OF CANDIDEMIA AND INVASIVE C...  \n",
       "10     3/24/2023  FOR THE TREATMENT OF ACTIVATED PHOSPHOINOSITID...  \n",
       "11     4/25/2023  FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLER...  \n",
       "12     5/12/2023  FOR THE TREATMENT OF MODERATE TO SEVERE VASOMO...  \n",
       "13     5/18/2023  FOR THE TREATMENT OF THE SIGNS AND SYMPTOMS OF...  \n",
       "14     5/23/2023  INDICATED IN PATIENTS 18 YEARS OF AGE AND OLDE...  \n",
       "15     5/25/2023  USE OF POSLUMA (FLOTUFOLASTAT F 18) FOR POSITR...  \n",
       "16     5/25/2023  FOR THE TREATMENT OF MILD-TO-MODERATE CORONAVI...  \n",
       "17     5/26/2023  INDICATED TO REDUCE THE RISK OF CARDIOVASCULAR...  \n",
       "18     6/23/2023  FOR THE TREATMENT OF SEVERE ALOPECIA AREATA (A...  \n",
       "19     7/20/2023  IN COMBINATION WITH STANDARD CYTARABINE AND AN...  \n",
       "20     7/24/2023           FOR THE TREATMENT OF DEMODEX BLEPHARITIS  \n",
       "21      8/4/2023  FOR THE TREATMENT OF GEOGRAPHIC ATROPHY (GA) S...  \n",
       "22      8/4/2023  FOR THE TREATMENT OF POSTPARTUM DEPRESSION (PP...  \n",
       "23     8/16/2023  FOR THE REDUCTION IN THE VOLUME OF NEW HETEROT...  \n",
       "24      9/8/2023  FOR USE IN COMBINATION WITH FILGRASTIM (G-CSF)...  \n",
       "25     9/15/2023  FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK...  \n",
       "26     9/22/2023  FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER...  \n",
       "27     9/29/2023  TO LOWER URINARY OXALATE LEVELS IN CHILDREN 9 ...  \n",
       "28    10/12/2023  FOR THE TREATMENT OF MODERATELY TO SEVERELY AC...  \n",
       "29    10/17/2023  FOR THE TREATMENT OF GENERALIZED MYASTHENIA GR...  \n",
       "30    10/26/2023  FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROP...  \n",
       "31     11/8/2023  FOR THE TREATMENT OF ADULT PATIENTS WITH METAS...  \n",
       "32    11/15/2023  TO REDUCE THE INCIDENCE OF CATHETER-RELATED BL...  \n",
       "33    11/15/2023  FOR THE TREATMENT OF ADULT PATIENTS WITH LOCAL...  \n",
       "34    11/16/2023  TRUQAP (CAPIVASERTIB) TABLETS IN COMBINATION W...  \n",
       "35    11/27/2023  FOR ADULT PATIENTS WITH PROGRESSING DESMOID TU...  \n",
       "36     12/5/2023  FOR THE TREATMENT OF ADULTS WITH PAROXYSMAL NO...  \n",
       "37    12/18/2023  FOR THE TREATMENT OF WOUNDS ASSOCIATED WITH DY...  \n",
       "38    12/21/2023  FOR THE TREATMENT OF THE POLYNEUROPATHY OF HER...  \n",
       "41      1/6/2023          FOR THE TREATMENT OF ALZHEIMER’S DISEASE.  \n",
       "42     2/16/2023  FOR THE TREATMENT OF THE NON-CENTRAL NERVOUS S...  \n",
       "43     3/22/2023  FOR THE TREATMENT OF ADULT PATIENTS WITH METAS...  \n",
       "44      5/9/2023  FOR THE TREATMENT OF ADULTS WITH CONFIRMED FAB...  \n",
       "45     5/19/2023  FOR THE TREATMENT OF ADULT PATIENTS WITH RELAP...  \n",
       "46     6/15/2023  FOR THE TREATMENT OF ADULT PATIENTS WITH RELAP...  \n",
       "47     6/26/2023  FOR THE TREATMENT OF GENERALIZED MYASTHENIA GR...  \n",
       "48     6/27/2023  FOR THE TREATMENT OF PEDIATRIC PATIENTS AGED 3...  \n",
       "49     7/17/2023  PREVENTION OF RSV LOWER RESPIRATORY TRACT DISE...  \n",
       "50      8/9/2023  FOR THE TREATMENT OF ADULT PATIENTS WITH RELAP...  \n",
       "51     8/14/2023  FOR THE TREATMENT OF ADULT PATIENTS WITH RELAP...  \n",
       "52     8/18/2023  VEOPOZ IS A COMPLEMENT INHIBITOR INDICATED FOR...  \n",
       "53     9/28/2023  IN COMBINATION WITH OPFOLDA, FOR THE TREATMENT...  \n",
       "54    10/17/2023  FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE...  \n",
       "55    10/26/2023  FOR ADULT PATIENTS WITH MODERATELY TO SEVERELY...  \n",
       "56    10/27/2023  LOQTORZI, IN COMBINATION WITH CISPLATIN AND GE...  \n",
       "57    11/16/2023  TO DECREASE THE INCIDENCE OF INFECTION, AS MAN...  "
      ],
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>APPLICATION NUMBER</th>\n",
       "      <th>PROPRIETARY NAME</th>\n",
       "      <th>ESTABLISHED NAME</th>\n",
       "      <th>APPLICANT</th>\n",
       "      <th>REVIEW CLASSIFICATION</th>\n",
       "      <th>APPROVAL DATE</th>\n",
       "      <th>INDICATION</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NDA 214373</td>\n",
       "      <td>BRENZAVVY</td>\n",
       "      <td>BEXAGLIFLOZIN</td>\n",
       "      <td>THERACOSBIO LLC</td>\n",
       "      <td>S</td>\n",
       "      <td>1/20/2023</td>\n",
       "      <td>ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEM...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NDA 216059</td>\n",
       "      <td>JAYPIRCA</td>\n",
       "      <td>PIRTOBRUTINIB</td>\n",
       "      <td>LOXO ONCOLOGY INC</td>\n",
       "      <td>P,O</td>\n",
       "      <td>1/27/2023</td>\n",
       "      <td>FOR THE TREATMENT OF ADULT PATIENTS WITH RELAP...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NDA 217639</td>\n",
       "      <td>ORSERDU</td>\n",
       "      <td>ELACESTRANT</td>\n",
       "      <td>STEMLINE THERAPEUTICS INC</td>\n",
       "      <td>P</td>\n",
       "      <td>1/27/2023</td>\n",
       "      <td>FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN OR A...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NDA 216951</td>\n",
       "      <td>JESDUVROQ</td>\n",
       "      <td>DAPRODUSTAT</td>\n",
       "      <td>GLAXOSMITHKLINE INTELLECTUAL PROPERTY NO 2 LTD...</td>\n",
       "      <td>S</td>\n",
       "      <td>2/1/2023</td>\n",
       "      <td>FOR THE TREATMENT OF ANEMIA DUE TO CHRONIC KID...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>NDA 216403</td>\n",
       "      <td>FILSPARI</td>\n",
       "      <td>SPARSENTAN</td>\n",
       "      <td>TRAVERE THERAPEUTICS INC</td>\n",
       "      <td>P,O</td>\n",
       "      <td>2/17/2023</td>\n",
       "      <td>TO REDUCE PROTEINURIA IN ADULTS WITH PRIMARY I...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>NDA 216718</td>\n",
       "      <td>SKYCLARYS</td>\n",
       "      <td>OMAVELOXOLONE</td>\n",
       "      <td>REATA PHARMACEUTICALS INC</td>\n",
       "      <td>P,O</td>\n",
       "      <td>2/28/2023</td>\n",
       "      <td>FOR THE TREATMENT OF FRIEDREICH'S ATAXIA IN AD...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>NDA 216386</td>\n",
       "      <td>ZAVZPRET</td>\n",
       "      <td>ZAVEGEPANT</td>\n",
       "      <td>PFIZER INC</td>\n",
       "      <td>S</td>\n",
       "      <td>3/9/2023</td>\n",
       "      <td>ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AU...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>NDA 217026</td>\n",
       "      <td>DAYBUE</td>\n",
       "      <td>TROFINETIDE</td>\n",
       "      <td>ACADIA PHARMACEUTICALS INC</td>\n",
       "      <td>P,O</td>\n",
       "      <td>3/10/2023</td>\n",
       "      <td>FOR THE TREATMENT OF RETT SYNDROME IN ADULTS A...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>NDA 217417</td>\n",
       "      <td>REZZAYO</td>\n",
       "      <td>REZAFUNGIN</td>\n",
       "      <td>CIDARA THERAPEUTICS INC</td>\n",
       "      <td>P,O</td>\n",
       "      <td>3/22/2023</td>\n",
       "      <td>FOR THE TREATMENT OF CANDIDEMIA AND INVASIVE C...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>NDA 217759</td>\n",
       "      <td>JOENJA</td>\n",
       "      <td>LENIOLISIB PHOSPHATE</td>\n",
       "      <td>PHARMING TECHNOLOGIES BV</td>\n",
       "      <td>P,O</td>\n",
       "      <td>3/24/2023</td>\n",
       "      <td>FOR THE TREATMENT OF ACTIVATED PHOSPHOINOSITID...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>NDA 215887</td>\n",
       "      <td>QALSODY</td>\n",
       "      <td>TOFERSEN</td>\n",
       "      <td>BIOGEN MA INC</td>\n",
       "      <td>P,O</td>\n",
       "      <td>4/25/2023</td>\n",
       "      <td>FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLER...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>NDA 216578</td>\n",
       "      <td>VEOZAH</td>\n",
       "      <td>FEZOLINETANT</td>\n",
       "      <td>ASTELLAS PHARMA US INC</td>\n",
       "      <td>P</td>\n",
       "      <td>5/12/2023</td>\n",
       "      <td>FOR THE TREATMENT OF MODERATE TO SEVERE VASOMO...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>NDA 216675</td>\n",
       "      <td>MIEBO</td>\n",
       "      <td>PERFLUOROHEXYLOCTANE</td>\n",
       "      <td>BAUSCH AND LOMB INC</td>\n",
       "      <td>S</td>\n",
       "      <td>5/18/2023</td>\n",
       "      <td>FOR THE TREATMENT OF THE SIGNS AND SYMPTOMS OF...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>NDA 216974</td>\n",
       "      <td>XACDURO</td>\n",
       "      <td>SULBACTAM FOR INJECTION; DURLOBACTAM FOR INJEC...</td>\n",
       "      <td>ENTASIS THERAPEUTICS INC</td>\n",
       "      <td>P</td>\n",
       "      <td>5/23/2023</td>\n",
       "      <td>INDICATED IN PATIENTS 18 YEARS OF AGE AND OLDE...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>NDA 216023</td>\n",
       "      <td>POSLUMA</td>\n",
       "      <td>FLOTUFOLASTAT F 18</td>\n",
       "      <td>BLUE EARTH DIAGNOSTICS LTD</td>\n",
       "      <td>S</td>\n",
       "      <td>5/25/2023</td>\n",
       "      <td>USE OF POSLUMA (FLOTUFOLASTAT F 18) FOR POSITR...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>NDA 217188</td>\n",
       "      <td>PAXLOVID</td>\n",
       "      <td>NIRMATRELVIR AND RITONAVIR</td>\n",
       "      <td>PFIZER INC</td>\n",
       "      <td>P</td>\n",
       "      <td>5/25/2023</td>\n",
       "      <td>FOR THE TREATMENT OF MILD-TO-MODERATE CORONAVI...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>NDA 216203</td>\n",
       "      <td>INPEFA</td>\n",
       "      <td>SOTAGLIFLOZIN</td>\n",
       "      <td>LEXICON PHARMACEUTICALS INC</td>\n",
       "      <td>S</td>\n",
       "      <td>5/26/2023</td>\n",
       "      <td>INDICATED TO REDUCE THE RISK OF CARDIOVASCULAR...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>NDA 215830</td>\n",
       "      <td>LITFULO</td>\n",
       "      <td>RITLECITINIB</td>\n",
       "      <td>PFIZER INC</td>\n",
       "      <td>S</td>\n",
       "      <td>6/23/2023</td>\n",
       "      <td>FOR THE TREATMENT OF SEVERE ALOPECIA AREATA (A...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>NDA 216993</td>\n",
       "      <td>VANFLYTA</td>\n",
       "      <td>QUIZARTINIB</td>\n",
       "      <td>DAIICHI SANKYO INC</td>\n",
       "      <td>P,O</td>\n",
       "      <td>7/20/2023</td>\n",
       "      <td>IN COMBINATION WITH STANDARD CYTARABINE AND AN...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>NDA 217603</td>\n",
       "      <td>XDEMVY</td>\n",
       "      <td>LOTILANER</td>\n",
       "      <td>TARSUS PHARMACEUTICALS INC</td>\n",
       "      <td>S</td>\n",
       "      <td>7/24/2023</td>\n",
       "      <td>FOR THE TREATMENT OF DEMODEX BLEPHARITIS</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>NDA 217225</td>\n",
       "      <td>IZERVAY</td>\n",
       "      <td>AVACINCAPTAD PEGOL</td>\n",
       "      <td>IVERIC BIO INC</td>\n",
       "      <td>P</td>\n",
       "      <td>8/4/2023</td>\n",
       "      <td>FOR THE TREATMENT OF GEOGRAPHIC ATROPHY (GA) S...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>NDA 217369</td>\n",
       "      <td>ZURZUVAE</td>\n",
       "      <td>ZURANOLONE</td>\n",
       "      <td>SAGE THERAPEUTICS INC</td>\n",
       "      <td>P</td>\n",
       "      <td>8/4/2023</td>\n",
       "      <td>FOR THE TREATMENT OF POSTPARTUM DEPRESSION (PP...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>NDA 215559</td>\n",
       "      <td>SOHONOS</td>\n",
       "      <td>PALOVAROTENE</td>\n",
       "      <td>IPSEN BIOPHARMACEUTICALS INC</td>\n",
       "      <td>P,O</td>\n",
       "      <td>8/16/2023</td>\n",
       "      <td>FOR THE REDUCTION IN THE VOLUME OF NEW HETEROT...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>NDA 217159</td>\n",
       "      <td>APHEXDA</td>\n",
       "      <td>MOTIXAFORTIDE</td>\n",
       "      <td>BIOLINERX LTD</td>\n",
       "      <td>S,O</td>\n",
       "      <td>9/8/2023</td>\n",
       "      <td>FOR USE IN COMBINATION WITH FILGRASTIM (G-CSF)...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>NDA 216873</td>\n",
       "      <td>OJJAARA</td>\n",
       "      <td>MOMELOTINIB</td>\n",
       "      <td>GLAXOSMITHKLINE LLC</td>\n",
       "      <td>S,O</td>\n",
       "      <td>9/15/2023</td>\n",
       "      <td>FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>NDA 021164</td>\n",
       "      <td>EXXUA</td>\n",
       "      <td>GEPIRONE</td>\n",
       "      <td>FABRE KRAMER PHARMACEUTICALS INC</td>\n",
       "      <td>S</td>\n",
       "      <td>9/22/2023</td>\n",
       "      <td>FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>NDA 215842</td>\n",
       "      <td>RIVFLOZA</td>\n",
       "      <td>NEDOSIRAN</td>\n",
       "      <td>NOVO NORDISK INC</td>\n",
       "      <td>S,O</td>\n",
       "      <td>9/29/2023</td>\n",
       "      <td>TO LOWER URINARY OXALATE LEVELS IN CHILDREN 9 ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>NDA 216956</td>\n",
       "      <td>VELSIPITY (ETRASIMOD)</td>\n",
       "      <td>ETRASIMOD</td>\n",
       "      <td>PFIZER INC</td>\n",
       "      <td>S</td>\n",
       "      <td>10/12/2023</td>\n",
       "      <td>FOR THE TREATMENT OF MODERATELY TO SEVERELY AC...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>NDA 216834</td>\n",
       "      <td>ZILBRYSQ (ZILUCOPLAN)</td>\n",
       "      <td>ZILUCOPLAN</td>\n",
       "      <td>UCB INC</td>\n",
       "      <td>S,O</td>\n",
       "      <td>10/17/2023</td>\n",
       "      <td>FOR THE TREATMENT OF GENERALIZED MYASTHENIA GR...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>NDA 215239</td>\n",
       "      <td>AGAMREE (VAMOROLONE)</td>\n",
       "      <td>VAMOROLONE</td>\n",
       "      <td>CATALYST PHARMACEUTICALS INC</td>\n",
       "      <td>S,O</td>\n",
       "      <td>10/26/2023</td>\n",
       "      <td>FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROP...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>NDA 217564</td>\n",
       "      <td>FRUZAQLA (FRUQUINTINIB)</td>\n",
       "      <td>FRUQUINTINIB</td>\n",
       "      <td>TAKEDA PHARMACEUTICALS USA INC</td>\n",
       "      <td>P</td>\n",
       "      <td>11/8/2023</td>\n",
       "      <td>FOR THE TREATMENT OF ADULT PATIENTS WITH METAS...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>NDA 214520</td>\n",
       "      <td>TAUROLIDINE AND HEPARIN CATHETER LOCK SOLUTION</td>\n",
       "      <td>TAUROLIDINE AND HEPARIN) CATHETER LOCK SOLUTION</td>\n",
       "      <td>CORMEDIX INC</td>\n",
       "      <td>P</td>\n",
       "      <td>11/15/2023</td>\n",
       "      <td>TO REDUCE THE INCIDENCE OF CATHETER-RELATED BL...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>NDA 218213</td>\n",
       "      <td>AUGTYRO</td>\n",
       "      <td>REPOTRECTINIB</td>\n",
       "      <td>BRISTOL MYERS SQUIBB CO</td>\n",
       "      <td>P,O</td>\n",
       "      <td>11/15/2023</td>\n",
       "      <td>FOR THE TREATMENT OF ADULT PATIENTS WITH LOCAL...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>NDA 218197</td>\n",
       "      <td>TRUQAP</td>\n",
       "      <td>CAPIVASERTIB</td>\n",
       "      <td>ASTRAZENECA PHARMACEUTICALS LP</td>\n",
       "      <td>P</td>\n",
       "      <td>11/16/2023</td>\n",
       "      <td>TRUQAP (CAPIVASERTIB) TABLETS IN COMBINATION W...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>NDA 217677</td>\n",
       "      <td>OGSIVEO</td>\n",
       "      <td>NIROGACESTAT</td>\n",
       "      <td>SPRINGWORKS THERAPEUTICS INC</td>\n",
       "      <td>P,O</td>\n",
       "      <td>11/27/2023</td>\n",
       "      <td>FOR ADULT PATIENTS WITH PROGRESSING DESMOID TU...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>NDA 218276</td>\n",
       "      <td>FABHALTA</td>\n",
       "      <td>IPTACOPAN</td>\n",
       "      <td>NOVARTIS PHARMACEUTICALS CORP</td>\n",
       "      <td>P,O</td>\n",
       "      <td>12/5/2023</td>\n",
       "      <td>FOR THE TREATMENT OF ADULTS WITH PAROXYSMAL NO...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>NDA 215064</td>\n",
       "      <td>FILSUVEZ</td>\n",
       "      <td>BIRCH TRITERPENES</td>\n",
       "      <td>CHIESI FARMACEUTICI SPA</td>\n",
       "      <td>P,O</td>\n",
       "      <td>12/18/2023</td>\n",
       "      <td>FOR THE TREATMENT OF WOUNDS ASSOCIATED WITH DY...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>NDA 217388</td>\n",
       "      <td>WAINUA</td>\n",
       "      <td>EPLONTERSEN</td>\n",
       "      <td>ASTRAZENECA AB</td>\n",
       "      <td>S,O</td>\n",
       "      <td>12/21/2023</td>\n",
       "      <td>FOR THE TREATMENT OF THE POLYNEUROPATHY OF HER...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>41</th>\n",
       "      <td>BLA 761269</td>\n",
       "      <td>LEQEMBI (LECANEMAB-IRMB)</td>\n",
       "      <td>LECANEMAB-IRMB)</td>\n",
       "      <td>EISAI, INCORPORATED</td>\n",
       "      <td>P</td>\n",
       "      <td>1/6/2023</td>\n",
       "      <td>FOR THE TREATMENT OF ALZHEIMER’S DISEASE.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>42</th>\n",
       "      <td>BLA 761278</td>\n",
       "      <td>LAMZEDE</td>\n",
       "      <td>VELMANASE ALFA-TYCV</td>\n",
       "      <td>CHIESI FARMACEUTICI S.P.A.</td>\n",
       "      <td>P,O</td>\n",
       "      <td>2/16/2023</td>\n",
       "      <td>FOR THE TREATMENT OF THE NON-CENTRAL NERVOUS S...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>43</th>\n",
       "      <td>BLA 761334</td>\n",
       "      <td>ZYNYZ</td>\n",
       "      <td>RETIFANLIMAB-DLWR</td>\n",
       "      <td>INCYTE CORPORATION</td>\n",
       "      <td>P,O</td>\n",
       "      <td>3/22/2023</td>\n",
       "      <td>FOR THE TREATMENT OF ADULT PATIENTS WITH METAS...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>44</th>\n",
       "      <td>BLA 761161</td>\n",
       "      <td>ELFABRIO</td>\n",
       "      <td>PEGUNIGALSIDASE ALFA- IWXJ</td>\n",
       "      <td>CHIESI FARMACEUTICI S.P.A.</td>\n",
       "      <td>P</td>\n",
       "      <td>5/9/2023</td>\n",
       "      <td>FOR THE TREATMENT OF ADULTS WITH CONFIRMED FAB...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>45</th>\n",
       "      <td>BLA 761324</td>\n",
       "      <td>EPKINLY</td>\n",
       "      <td>EPCORITAMAB-BYSP</td>\n",
       "      <td>GENMAB US, INC.</td>\n",
       "      <td>P</td>\n",
       "      <td>5/19/2023</td>\n",
       "      <td>FOR THE TREATMENT OF ADULT PATIENTS WITH RELAP...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>46</th>\n",
       "      <td>BLA 761309</td>\n",
       "      <td>COLUMVI</td>\n",
       "      <td>GLOFITAMAB-GXBM)</td>\n",
       "      <td>GENENTECH, INC.</td>\n",
       "      <td>P</td>\n",
       "      <td>6/15/2023</td>\n",
       "      <td>FOR THE TREATMENT OF ADULT PATIENTS WITH RELAP...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>47</th>\n",
       "      <td>BLA 761286</td>\n",
       "      <td>RYSTIGGO</td>\n",
       "      <td>ROZANOLIXIZUMAB-NOLI</td>\n",
       "      <td>UCB, INC.</td>\n",
       "      <td>P,O</td>\n",
       "      <td>6/26/2023</td>\n",
       "      <td>FOR THE TREATMENT OF GENERALIZED MYASTHENIA GR...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>48</th>\n",
       "      <td>BLA 761184</td>\n",
       "      <td>NGENLA (SOMATROGON-GHLA)</td>\n",
       "      <td>SOMATROGON-GHLA</td>\n",
       "      <td>PFIZER IRELAND PHARMACEUTICALS</td>\n",
       "      <td>S,O</td>\n",
       "      <td>6/27/2023</td>\n",
       "      <td>FOR THE TREATMENT OF PEDIATRIC PATIENTS AGED 3...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>49</th>\n",
       "      <td>BLA 761328</td>\n",
       "      <td>BEYFORTUS</td>\n",
       "      <td>NIRSEVIMAB-ALIP</td>\n",
       "      <td>ASTRAZENECA AB</td>\n",
       "      <td>S</td>\n",
       "      <td>7/17/2023</td>\n",
       "      <td>PREVENTION OF RSV LOWER RESPIRATORY TRACT DISE...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>50</th>\n",
       "      <td>BLA 761342</td>\n",
       "      <td>TALVEY</td>\n",
       "      <td>TALQUETAMAB-TGVS</td>\n",
       "      <td>JANSSEN BIOTECH, INC.</td>\n",
       "      <td>P,O</td>\n",
       "      <td>8/9/2023</td>\n",
       "      <td>FOR THE TREATMENT OF ADULT PATIENTS WITH RELAP...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>51</th>\n",
       "      <td>BLA 761345</td>\n",
       "      <td>ELREXFIO</td>\n",
       "      <td>ELRANATAMAB-BCMM</td>\n",
       "      <td>PFIZER INC.</td>\n",
       "      <td>P,O</td>\n",
       "      <td>8/14/2023</td>\n",
       "      <td>FOR THE TREATMENT OF ADULT PATIENTS WITH RELAP...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>52</th>\n",
       "      <td>BLA 761339</td>\n",
       "      <td>VEOPOZ</td>\n",
       "      <td>POZELIMAB-BBFG</td>\n",
       "      <td>REGENERON PHARMACEUTICALS, INC.</td>\n",
       "      <td>P,O</td>\n",
       "      <td>8/18/2023</td>\n",
       "      <td>VEOPOZ IS A COMPLEMENT INHIBITOR INDICATED FOR...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>53</th>\n",
       "      <td>BLA 761204</td>\n",
       "      <td>POMBILITI</td>\n",
       "      <td>CIPAGLUCOSIDASE ALFA- ATGA</td>\n",
       "      <td>AMICUS THERAPEUTICS US, LLC</td>\n",
       "      <td>S</td>\n",
       "      <td>9/28/2023</td>\n",
       "      <td>IN COMBINATION WITH OPFOLDA, FOR THE TREATMENT...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>54</th>\n",
       "      <td>BLA 761151</td>\n",
       "      <td>BIMZELX</td>\n",
       "      <td>BIMEKIZUMAB</td>\n",
       "      <td>UCB, INC.</td>\n",
       "      <td>S</td>\n",
       "      <td>10/17/2023</td>\n",
       "      <td>FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>55</th>\n",
       "      <td>BLA 761279</td>\n",
       "      <td>OMVOH</td>\n",
       "      <td>MIRIKIZUMAB-MRKZ</td>\n",
       "      <td>ELI LILLY AND COMPANY</td>\n",
       "      <td>S,O</td>\n",
       "      <td>10/26/2023</td>\n",
       "      <td>FOR ADULT PATIENTS WITH MODERATELY TO SEVERELY...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>56</th>\n",
       "      <td>BLA 761240</td>\n",
       "      <td>LOQTORZI</td>\n",
       "      <td>TORIPALIMAB-TPZI</td>\n",
       "      <td>COHERUS BIOSCIENCES, INC.</td>\n",
       "      <td>P,O</td>\n",
       "      <td>10/27/2023</td>\n",
       "      <td>LOQTORZI, IN COMBINATION WITH CISPLATIN AND GE...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>57</th>\n",
       "      <td>BLA 761134</td>\n",
       "      <td>RYZNEUTA</td>\n",
       "      <td>EFBEMALENOGRASTIM ALFA-VUXW)</td>\n",
       "      <td>EVIVE BIOTECHNOLOGY SINGAPORE PTE. LTD.</td>\n",
       "      <td>S</td>\n",
       "      <td>11/16/2023</td>\n",
       "      <td>TO DECREASE THE INCIDENCE OF INFECTION, AS MAN...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "execution_count": 4
  },
  {
   "metadata": {},
   "cell_type": "markdown",
   "source": [
    "### Extract Table From Multiple Years\n",
    "The above example is great for a single year. Multiple years can be obtained using a loop. The link dictionary demoed above will be looped and the table for each key/item pair will be extracted. Then the tables will be combined to generate a single pd.DataFrame for NME across the indicated years. "
   ]
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-07-23T09:43:44.702427Z",
     "start_time": "2024-07-23T09:43:42.976770Z"
    }
   },
   "cell_type": "code",
   "source": [
    "# Empty list to hold pd.DataFrame\n",
    "tables = []\n",
    "\n",
    "# Extract table for all years in dictionary\n",
    "for year, table in links.items():\n",
    "    data = scrape.extract_table(year=year)\n",
    "    tables.append(data)\n",
    "    \n",
    "# Combine tables into a single pd.DataFrame\n",
    "tables = pd.concat(tables, ignore_index=True)\n",
    "tables"
   ],
   "outputs": [
    {
     "data": {
      "text/plain": [
       "    APPLICATION NUMBER PROPRIETARY NAME ESTABLISHED NAME  \\\n",
       "0           NDA 214373        BRENZAVVY    BEXAGLIFLOZIN   \n",
       "1           NDA 216059         JAYPIRCA    PIRTOBRUTINIB   \n",
       "2           NDA 217639          ORSERDU      ELACESTRANT   \n",
       "3           NDA 216951        JESDUVROQ      DAPRODUSTAT   \n",
       "4           NDA 216403         FILSPARI       SPARSENTAN   \n",
       "..                 ...              ...              ...   \n",
       "300     BLA 125526/0.0           NUCALA      MEPOLIZUMAB   \n",
       "301     BLA 761036/0.0         DARZALEX      DARATUMUMAB   \n",
       "302     BLA 125547/0.0        PORTRAZZA      NECITUMUMAB   \n",
       "303     BLA 761035/0.0        EMPLICITI       ELOTUZUMAB   \n",
       "304     BLA 125561/0.0           KANUMA  SEBELIPASE ALFA   \n",
       "\n",
       "                                             APPLICANT REVIEW CLASSIFICATION  \\\n",
       "0                                      THERACOSBIO LLC                     S   \n",
       "1                                    LOXO ONCOLOGY INC                   P,O   \n",
       "2                            STEMLINE THERAPEUTICS INC                     P   \n",
       "3    GLAXOSMITHKLINE INTELLECTUAL PROPERTY NO 2 LTD...                     S   \n",
       "4                             TRAVERE THERAPEUTICS INC                   P,O   \n",
       "..                                                 ...                   ...   \n",
       "300                                GLAXOSMITHKLINE LLC                     S   \n",
       "301                              JANSSEN BIOTECH, INC.                   P,O   \n",
       "302                              ELI LILLY AND COMPANY                     S   \n",
       "303                       BRISTOL-MYERS SQUIBB COMPANY                   P,O   \n",
       "304                            SYNAGEVA BIOPHARMA CORP                   P,O   \n",
       "\n",
       "    APPROVAL DATE                                         INDICATION  \\\n",
       "0       1/20/2023  ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEM...   \n",
       "1       1/27/2023  FOR THE TREATMENT OF ADULT PATIENTS WITH RELAP...   \n",
       "2       1/27/2023  FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN OR A...   \n",
       "3        2/1/2023  FOR THE TREATMENT OF ANEMIA DUE TO CHRONIC KID...   \n",
       "4       2/17/2023  TO REDUCE PROTEINURIA IN ADULTS WITH PRIMARY I...   \n",
       "..            ...                                                ...   \n",
       "300     11/4/2015  INDICATED FOR THE ADD-ON MAINTENANCE TREATMENT...   \n",
       "301    11/16/2015  INDICATED FOR TREATMENT OF PATIENTS WITH MULTI...   \n",
       "302    11/24/2015  IS INDICATED, IN COMBINATION WITH GEMCITABINE ...   \n",
       "303    11/30/2015  INDICATED IN COMBINATION WITH LENALIDOMIDE AND...   \n",
       "304     12/8/2015  INDICATED FOR THE TREATMENT OF PATIENTS WITH A...   \n",
       "\n",
       "    CY 2020 CDER New Molecular Entity (NME) Drug & Original BLA Calendar Year Approvals\\rAs of Decemeber 31, 2020\\rThis report reflects the data shown as it is identified in the database.\\rSelection Criteria:\\rUser Response: Start Date: 1/1/2020    End Date: 12/31/2020\\rSort Order: Approval Date  \\\n",
       "0                                                  NaN                                                                                                                                                                                                                                                     \n",
       "1                                                  NaN                                                                                                                                                                                                                                                     \n",
       "2                                                  NaN                                                                                                                                                                                                                                                     \n",
       "3                                                  NaN                                                                                                                                                                                                                                                     \n",
       "4                                                  NaN                                                                                                                                                                                                                                                     \n",
       "..                                                 ...                                                                                                                                                                                                                                                     \n",
       "300                                                NaN                                                                                                                                                                                                                                                     \n",
       "301                                                NaN                                                                                                                                                                                                                                                     \n",
       "302                                                NaN                                                                                                                                                                                                                                                     \n",
       "303                                                NaN                                                                                                                                                                                                                                                     \n",
       "304                                                NaN                                                                                                                                                                                                                                                     \n",
       "\n",
       "    Unnamed: 1_level_0 Unnamed: 2_level_0 Unnamed: 3_level_0  \\\n",
       "0                  NaN                NaN                NaN   \n",
       "1                  NaN                NaN                NaN   \n",
       "2                  NaN                NaN                NaN   \n",
       "3                  NaN                NaN                NaN   \n",
       "4                  NaN                NaN                NaN   \n",
       "..                 ...                ...                ...   \n",
       "300                NaN                NaN                NaN   \n",
       "301                NaN                NaN                NaN   \n",
       "302                NaN                NaN                NaN   \n",
       "303                NaN                NaN                NaN   \n",
       "304                NaN                NaN                NaN   \n",
       "\n",
       "    Unnamed: 4_level_0 Unnamed: 5_level_0 Unnamed: 6_level_0  \\\n",
       "0                  NaN                NaN                NaN   \n",
       "1                  NaN                NaN                NaN   \n",
       "2                  NaN                NaN                NaN   \n",
       "3                  NaN                NaN                NaN   \n",
       "4                  NaN                NaN                NaN   \n",
       "..                 ...                ...                ...   \n",
       "300                NaN                NaN                NaN   \n",
       "301                NaN                NaN                NaN   \n",
       "302                NaN                NaN                NaN   \n",
       "303                NaN                NaN                NaN   \n",
       "304                NaN                NaN                NaN   \n",
       "\n",
       "    Unnamed: 7_level_0  \\\n",
       "0                  NaN   \n",
       "1                  NaN   \n",
       "2                  NaN   \n",
       "3                  NaN   \n",
       "4                  NaN   \n",
       "..                 ...   \n",
       "300                NaN   \n",
       "301                NaN   \n",
       "302                NaN   \n",
       "303                NaN   \n",
       "304                NaN   \n",
       "\n",
       "    CY 2018 CDER New Molecular Entity (NME) Drug & Original BLA Calendar Year Approvals\\rAs of December 31, 2018\\rThis report reflects the data shown as it is identified in the database.\\rSelection Criteria:\\rUser Response: Start Date: 1/1/2018    End Date: 12/31/2018\\rSort Order: Approval Date  \n",
       "0                                                  NaN                                                                                                                                                                                                                                                   \n",
       "1                                                  NaN                                                                                                                                                                                                                                                   \n",
       "2                                                  NaN                                                                                                                                                                                                                                                   \n",
       "3                                                  NaN                                                                                                                                                                                                                                                   \n",
       "4                                                  NaN                                                                                                                                                                                                                                                   \n",
       "..                                                 ...                                                                                                                                                                                                                                                   \n",
       "300                                                NaN                                                                                                                                                                                                                                                   \n",
       "301                                                NaN                                                                                                                                                                                                                                                   \n",
       "302                                                NaN                                                                                                                                                                                                                                                   \n",
       "303                                                NaN                                                                                                                                                                                                                                                   \n",
       "304                                                NaN                                                                                                                                                                                                                                                   \n",
       "\n",
       "[305 rows x 16 columns]"
      ],
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>APPLICATION NUMBER</th>\n",
       "      <th>PROPRIETARY NAME</th>\n",
       "      <th>ESTABLISHED NAME</th>\n",
       "      <th>APPLICANT</th>\n",
       "      <th>REVIEW CLASSIFICATION</th>\n",
       "      <th>APPROVAL DATE</th>\n",
       "      <th>INDICATION</th>\n",
       "      <th>CY 2020 CDER New Molecular Entity (NME) Drug &amp; Original BLA Calendar Year Approvals\\rAs of Decemeber 31, 2020\\rThis report reflects the data shown as it is identified in the database.\\rSelection Criteria:\\rUser Response: Start Date: 1/1/2020    End Date: 12/31/2020\\rSort Order: Approval Date</th>\n",
       "      <th>Unnamed: 1_level_0</th>\n",
       "      <th>Unnamed: 2_level_0</th>\n",
       "      <th>Unnamed: 3_level_0</th>\n",
       "      <th>Unnamed: 4_level_0</th>\n",
       "      <th>Unnamed: 5_level_0</th>\n",
       "      <th>Unnamed: 6_level_0</th>\n",
       "      <th>Unnamed: 7_level_0</th>\n",
       "      <th>CY 2018 CDER New Molecular Entity (NME) Drug &amp; Original BLA Calendar Year Approvals\\rAs of December 31, 2018\\rThis report reflects the data shown as it is identified in the database.\\rSelection Criteria:\\rUser Response: Start Date: 1/1/2018    End Date: 12/31/2018\\rSort Order: Approval Date</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NDA 214373</td>\n",
       "      <td>BRENZAVVY</td>\n",
       "      <td>BEXAGLIFLOZIN</td>\n",
       "      <td>THERACOSBIO LLC</td>\n",
       "      <td>S</td>\n",
       "      <td>1/20/2023</td>\n",
       "      <td>ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEM...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NDA 216059</td>\n",
       "      <td>JAYPIRCA</td>\n",
       "      <td>PIRTOBRUTINIB</td>\n",
       "      <td>LOXO ONCOLOGY INC</td>\n",
       "      <td>P,O</td>\n",
       "      <td>1/27/2023</td>\n",
       "      <td>FOR THE TREATMENT OF ADULT PATIENTS WITH RELAP...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NDA 217639</td>\n",
       "      <td>ORSERDU</td>\n",
       "      <td>ELACESTRANT</td>\n",
       "      <td>STEMLINE THERAPEUTICS INC</td>\n",
       "      <td>P</td>\n",
       "      <td>1/27/2023</td>\n",
       "      <td>FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN OR A...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NDA 216951</td>\n",
       "      <td>JESDUVROQ</td>\n",
       "      <td>DAPRODUSTAT</td>\n",
       "      <td>GLAXOSMITHKLINE INTELLECTUAL PROPERTY NO 2 LTD...</td>\n",
       "      <td>S</td>\n",
       "      <td>2/1/2023</td>\n",
       "      <td>FOR THE TREATMENT OF ANEMIA DUE TO CHRONIC KID...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NDA 216403</td>\n",
       "      <td>FILSPARI</td>\n",
       "      <td>SPARSENTAN</td>\n",
       "      <td>TRAVERE THERAPEUTICS INC</td>\n",
       "      <td>P,O</td>\n",
       "      <td>2/17/2023</td>\n",
       "      <td>TO REDUCE PROTEINURIA IN ADULTS WITH PRIMARY I...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>300</th>\n",
       "      <td>BLA 125526/0.0</td>\n",
       "      <td>NUCALA</td>\n",
       "      <td>MEPOLIZUMAB</td>\n",
       "      <td>GLAXOSMITHKLINE LLC</td>\n",
       "      <td>S</td>\n",
       "      <td>11/4/2015</td>\n",
       "      <td>INDICATED FOR THE ADD-ON MAINTENANCE TREATMENT...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>301</th>\n",
       "      <td>BLA 761036/0.0</td>\n",
       "      <td>DARZALEX</td>\n",
       "      <td>DARATUMUMAB</td>\n",
       "      <td>JANSSEN BIOTECH, INC.</td>\n",
       "      <td>P,O</td>\n",
       "      <td>11/16/2015</td>\n",
       "      <td>INDICATED FOR TREATMENT OF PATIENTS WITH MULTI...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>302</th>\n",
       "      <td>BLA 125547/0.0</td>\n",
       "      <td>PORTRAZZA</td>\n",
       "      <td>NECITUMUMAB</td>\n",
       "      <td>ELI LILLY AND COMPANY</td>\n",
       "      <td>S</td>\n",
       "      <td>11/24/2015</td>\n",
       "      <td>IS INDICATED, IN COMBINATION WITH GEMCITABINE ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>303</th>\n",
       "      <td>BLA 761035/0.0</td>\n",
       "      <td>EMPLICITI</td>\n",
       "      <td>ELOTUZUMAB</td>\n",
       "      <td>BRISTOL-MYERS SQUIBB COMPANY</td>\n",
       "      <td>P,O</td>\n",
       "      <td>11/30/2015</td>\n",
       "      <td>INDICATED IN COMBINATION WITH LENALIDOMIDE AND...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>304</th>\n",
       "      <td>BLA 125561/0.0</td>\n",
       "      <td>KANUMA</td>\n",
       "      <td>SEBELIPASE ALFA</td>\n",
       "      <td>SYNAGEVA BIOPHARMA CORP</td>\n",
       "      <td>P,O</td>\n",
       "      <td>12/8/2015</td>\n",
       "      <td>INDICATED FOR THE TREATMENT OF PATIENTS WITH A...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>305 rows × 16 columns</p>\n",
       "</div>"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "execution_count": 5
  },
  {
   "metadata": {},
   "cell_type": "markdown",
   "source": [
    "### Get Compilation Data\n",
    "\n",
    "The FDA contains a site containing [Compilation Dataset links](https://www.fda.gov/drugs/drug-approvals-and-databases/compilation-cder-new-molecular-entity-nme-drug-and-new-biologic-approvals). This link points to a .csv file that can be downloaded and converted into a pd.DataFrame. This is already handled by FDAScrapper.\n",
    "\n",
    "If there are updates to the Compilation Dataset page, a different URL can be tested by passing in the url to the \"url\" parameter.  \n",
    "\n",
    "As of this writing, the compilation dataset contains **NME and New Biologic Approvals from 1985-2023**"
   ]
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-07-23T09:43:44.850911Z",
     "start_time": "2024-07-23T09:43:44.703241Z"
    }
   },
   "cell_type": "code",
   "source": [
    "compilation = scrape.get_compilation()\n",
    "compilation"
   ],
   "outputs": [
    {
     "data": {
      "text/plain": [
       "     Proprietary  Name     Active Ingredient/Moiety  \\\n",
       "0               Lupron           leuprolide acetate   \n",
       "1              Seldane                  terfenadine   \n",
       "2              Ridaura                    auranofin   \n",
       "3              Marinol                   dronabinol   \n",
       "4               Fortaz                  ceftazidime   \n",
       "...                ...                          ...   \n",
       "1286          Ryzneuta  efbemalenograstim alfa-vuxw   \n",
       "1287           Ogsiveo                 nirogacestat   \n",
       "1288          Fabhalta                    iptacopan   \n",
       "1289          Filsuvez            birch triterpenes   \n",
       "1290            Wainua                  eplontersen   \n",
       "\n",
       "                                    Applicant NDA/BLA   Application Number(1)  \\\n",
       "0                         TAP Pharmaceuticals     NDA                   19010   \n",
       "1                                 Merrell-Dow     NDA                   18949   \n",
       "2                         SmithKline & French     NDA                   18689   \n",
       "3                                      Unimed     NDA                   18651   \n",
       "4                                       Glaxo     NDA                   50578   \n",
       "...                                       ...     ...                     ...   \n",
       "1286  Evive Biotechnology Singapore PTE. Ltd.     BLA                  761134   \n",
       "1287           SpringWorks Therapeutics, Inc.     NDA                  217677   \n",
       "1288     Novartis Pharmaceuticals Corporation     NDA                  218276   \n",
       "1289                Amryt Pharmaceuticals DAC     NDA                  215064   \n",
       "1290              Ionis Pharmaceuticals, Inc.     NDA                  217388   \n",
       "\n",
       "       Application Number(2)   Application Number(3) Dosage Form(1)  \\\n",
       "0                        NaN                     NaN     Injectable   \n",
       "1                        NaN                     NaN         Tablet   \n",
       "2                        NaN                     NaN        Capsule   \n",
       "3                        NaN                     NaN        Capsule   \n",
       "4                        NaN                     NaN     Injectable   \n",
       "...                      ...                     ...            ...   \n",
       "1286                     NaN                     NaN     Injectable   \n",
       "1287                     NaN                     NaN         Tablet   \n",
       "1288                     NaN                     NaN        Capsule   \n",
       "1289                     NaN                     NaN            Gel   \n",
       "1290                     NaN                     NaN     Injectable   \n",
       "\n",
       "     Route of Administration(1) Dosage Form(2)  ...  \\\n",
       "0                     Injection            NaN  ...   \n",
       "1                          Oral            NaN  ...   \n",
       "2                          Oral            NaN  ...   \n",
       "3                          Oral            NaN  ...   \n",
       "4                     Injection            NaN  ...   \n",
       "...                         ...            ...  ...   \n",
       "1286                  Injection            NaN  ...   \n",
       "1287                       Oral            NaN  ...   \n",
       "1288                       Oral            NaN  ...   \n",
       "1289                    Topical            NaN  ...   \n",
       "1290                  Injection            NaN  ...   \n",
       "\n",
       "                                        Approved Use(s)  \\\n",
       "0                                                   NaN   \n",
       "1                                                   NaN   \n",
       "2                                                   NaN   \n",
       "3                                                   NaN   \n",
       "4                                                   NaN   \n",
       "...                                                 ...   \n",
       "1286  RYZNEUTA is indicated to decrease the incidenc...   \n",
       "1287  OGSIVEO is indicated for adult patients with p...   \n",
       "1288  FABHALTA is indicated for the treatment of adu...   \n",
       "1289  FILSUVEZ topical gel is indicated for the trea...   \n",
       "1290  WAINUA is indicated for the treatment of the p...   \n",
       "\n",
       "                           Review Designation Orphan Drug Designation  \\\n",
       "0                                    Priority                      No   \n",
       "1                                    Priority                      No   \n",
       "2                                    Priority                      No   \n",
       "3                                    Priority                      No   \n",
       "4                                    Priority                      No   \n",
       "...                                       ...                     ...   \n",
       "1286                                 Standard                      No   \n",
       "1287                                 Priority                     Yes   \n",
       "1288  Priority (used priority review voucher)                     Yes   \n",
       "1289                                 Priority                     Yes   \n",
       "1290                                 Standard                     Yes   \n",
       "\n",
       "     Accelerated Approval Breakthrough Therapy Designation  \\\n",
       "0                     NaN                              NaN   \n",
       "1                     NaN                              NaN   \n",
       "2                     NaN                              NaN   \n",
       "3                     NaN                              NaN   \n",
       "4                     NaN                              NaN   \n",
       "...                   ...                              ...   \n",
       "1286                   No                               No   \n",
       "1287                   No                              Yes   \n",
       "1288                   No                              Yes   \n",
       "1289                   No                               No   \n",
       "1290                   No                               No   \n",
       "\n",
       "      Fast Track Designation Qualified Infectious Disease Product  \\\n",
       "0                        NaN                                  NaN   \n",
       "1                        NaN                                  NaN   \n",
       "2                        NaN                                  NaN   \n",
       "3                        NaN                                  NaN   \n",
       "4                        NaN                                  NaN   \n",
       "...                      ...                                  ...   \n",
       "1286                      No                                  NaN   \n",
       "1287                     Yes                                   No   \n",
       "1288                      No                                   No   \n",
       "1289                     Yes                                   No   \n",
       "1290                      No                                   No   \n",
       "\n",
       "     Issued a Priority Review Voucher Redeemed a Priority Review Voucher Notes  \n",
       "0                                 NaN                                NaN   NaN  \n",
       "1                                 NaN                                NaN   NaN  \n",
       "2                                 NaN                                NaN   NaN  \n",
       "3                                 NaN                                NaN   NaN  \n",
       "4                                 NaN                                NaN   NaN  \n",
       "...                               ...                                ...   ...  \n",
       "1286                               No                                 No   NaN  \n",
       "1287                               No                                 No   NaN  \n",
       "1288                               No                                Yes   NaN  \n",
       "1289                              RPD                                 No   NaN  \n",
       "1290                               No                                 No   NaN  \n",
       "\n",
       "[1291 rows x 27 columns]"
      ],
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Proprietary  Name</th>\n",
       "      <th>Active Ingredient/Moiety</th>\n",
       "      <th>Applicant</th>\n",
       "      <th>NDA/BLA</th>\n",
       "      <th>Application Number(1)</th>\n",
       "      <th>Application Number(2)</th>\n",
       "      <th>Application Number(3)</th>\n",
       "      <th>Dosage Form(1)</th>\n",
       "      <th>Route of Administration(1)</th>\n",
       "      <th>Dosage Form(2)</th>\n",
       "      <th>...</th>\n",
       "      <th>Approved Use(s)</th>\n",
       "      <th>Review Designation</th>\n",
       "      <th>Orphan Drug Designation</th>\n",
       "      <th>Accelerated Approval</th>\n",
       "      <th>Breakthrough Therapy Designation</th>\n",
       "      <th>Fast Track Designation</th>\n",
       "      <th>Qualified Infectious Disease Product</th>\n",
       "      <th>Issued a Priority Review Voucher</th>\n",
       "      <th>Redeemed a Priority Review Voucher</th>\n",
       "      <th>Notes</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Lupron</td>\n",
       "      <td>leuprolide acetate</td>\n",
       "      <td>TAP Pharmaceuticals</td>\n",
       "      <td>NDA</td>\n",
       "      <td>19010</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Injectable</td>\n",
       "      <td>Injection</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Priority</td>\n",
       "      <td>No</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Seldane</td>\n",
       "      <td>terfenadine</td>\n",
       "      <td>Merrell-Dow</td>\n",
       "      <td>NDA</td>\n",
       "      <td>18949</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tablet</td>\n",
       "      <td>Oral</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Priority</td>\n",
       "      <td>No</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Ridaura</td>\n",
       "      <td>auranofin</td>\n",
       "      <td>SmithKline &amp; French</td>\n",
       "      <td>NDA</td>\n",
       "      <td>18689</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Capsule</td>\n",
       "      <td>Oral</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Priority</td>\n",
       "      <td>No</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Marinol</td>\n",
       "      <td>dronabinol</td>\n",
       "      <td>Unimed</td>\n",
       "      <td>NDA</td>\n",
       "      <td>18651</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Capsule</td>\n",
       "      <td>Oral</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Priority</td>\n",
       "      <td>No</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Fortaz</td>\n",
       "      <td>ceftazidime</td>\n",
       "      <td>Glaxo</td>\n",
       "      <td>NDA</td>\n",
       "      <td>50578</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Injectable</td>\n",
       "      <td>Injection</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Priority</td>\n",
       "      <td>No</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1286</th>\n",
       "      <td>Ryzneuta</td>\n",
       "      <td>efbemalenograstim alfa-vuxw</td>\n",
       "      <td>Evive Biotechnology Singapore PTE. Ltd.</td>\n",
       "      <td>BLA</td>\n",
       "      <td>761134</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Injectable</td>\n",
       "      <td>Injection</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>RYZNEUTA is indicated to decrease the incidenc...</td>\n",
       "      <td>Standard</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>NaN</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1287</th>\n",
       "      <td>Ogsiveo</td>\n",
       "      <td>nirogacestat</td>\n",
       "      <td>SpringWorks Therapeutics, Inc.</td>\n",
       "      <td>NDA</td>\n",
       "      <td>217677</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tablet</td>\n",
       "      <td>Oral</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>OGSIVEO is indicated for adult patients with p...</td>\n",
       "      <td>Priority</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>Yes</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1288</th>\n",
       "      <td>Fabhalta</td>\n",
       "      <td>iptacopan</td>\n",
       "      <td>Novartis Pharmaceuticals Corporation</td>\n",
       "      <td>NDA</td>\n",
       "      <td>218276</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Capsule</td>\n",
       "      <td>Oral</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>FABHALTA is indicated for the treatment of adu...</td>\n",
       "      <td>Priority (used priority review voucher)</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>Yes</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1289</th>\n",
       "      <td>Filsuvez</td>\n",
       "      <td>birch triterpenes</td>\n",
       "      <td>Amryt Pharmaceuticals DAC</td>\n",
       "      <td>NDA</td>\n",
       "      <td>215064</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Gel</td>\n",
       "      <td>Topical</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>FILSUVEZ topical gel is indicated for the trea...</td>\n",
       "      <td>Priority</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>RPD</td>\n",
       "      <td>No</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1290</th>\n",
       "      <td>Wainua</td>\n",
       "      <td>eplontersen</td>\n",
       "      <td>Ionis Pharmaceuticals, Inc.</td>\n",
       "      <td>NDA</td>\n",
       "      <td>217388</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Injectable</td>\n",
       "      <td>Injection</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>WAINUA is indicated for the treatment of the p...</td>\n",
       "      <td>Standard</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>No</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1291 rows × 27 columns</p>\n",
       "</div>"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "execution_count": 6
  },
  {
   "metadata": {},
   "cell_type": "markdown",
   "source": [
    "# Get Current Approvals for Current Year\n",
    "\n",
    "Finally, the FDA curates [Novel Drug Approvals](https://www.fda.gov/drugs/development-approval-process-drugs/novel-drug-approvals-fda) for a given year. Information from this page can be used to obtain the current year drug approvals.\n",
    "\n",
    "A downside to this page is that it does not properly designate a drug as New Drug Application (NDA) or Biologics License Application (BLA). This would indicate small-molecule or biologics, respectively. A rule of thumb can be taken by the active ingredient names, where drugs ending in \"mab\" and \"cept\" can indicate biologics. However, confirmation should still be performed to ensure labeling accuracy.   "
   ]
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-07-23T09:43:44.958608Z",
     "start_time": "2024-07-23T09:43:44.851658Z"
    }
   },
   "cell_type": "code",
   "source": [
    "latest = scrape.get_current_year()\n",
    "latest"
   ],
   "outputs": [
    {
     "data": {
      "text/plain": [
       "    Drug Name                  Active Ingredient Approval Date  \\\n",
       "0     Kisunla                     donanemab-azbt      7/2/2024   \n",
       "1   Ohtuvayre                       ensifentrine     6/26/2024   \n",
       "2      Piasky                    crovalimab-akkz     6/20/2024   \n",
       "3      Sofdra                        sofpironium     6/18/2024   \n",
       "4      Iqirvo                        elafibranor     6/10/2024   \n",
       "5      Rytelo                         imetelstat      6/6/2024   \n",
       "6   Imdelltra                    tarlatamab-dlle     5/16/2024   \n",
       "7    Xolremdi                        mavorixafor     4/26/2024   \n",
       "8      Ojemda                        tovorafenib     4/23/2024   \n",
       "9     Anktiva  nogapendekin alfa inbakicept-pmln     4/22/2024   \n",
       "10  Lumisight                      pegulicianine     4/17/2024   \n",
       "11    Zevtera      ceftobiprole medocaril sodium      4/3/2024   \n",
       "12    Voydeya                          danicopan     3/29/2024   \n",
       "13     Vafseo                         vadadustat     3/27/2024   \n",
       "14  Winrevair                   sotatercept-csrk     3/26/2024   \n",
       "15    Duvyzat                         givinostat     3/21/2024   \n",
       "16     Tryvio                       aprocitentan     3/19/2024   \n",
       "17  Rezdiffra                         resmetirom     3/14/2024   \n",
       "18   Tevimbra                  tislelizumab-jsgr     3/13/2024   \n",
       "19     Letybo           letibotulinumtoxinA-wlbg     2/29/2024   \n",
       "20   Exblifep           cefepime, enmetazobactam     2/22/2024   \n",
       "21   Zelsuvmi                         berdazimer      1/5/2024   \n",
       "\n",
       "                   FDA-approved use on approval date*  \n",
       "0                        To treat Alzheimer’s disease  \n",
       "1      To treat chronic obstructive pulmonary disease  \n",
       "2        To treat paroxysmal nocturnal hemoglobinuria  \n",
       "3             To treat primary axillary hyperhidrosis  \n",
       "4   To treat primary biliary cholangitis in combin...  \n",
       "5   To treat low- to intermediate-1 risk myelodysp...  \n",
       "6     To treat extensive stage small cell lung cancer  \n",
       "7   To treat WHIM syndrome (warts, hypogammaglobul...  \n",
       "8   To treat relapsed or refractory pediatric low-...  \n",
       "9                             To treat bladder cancer  \n",
       "10  To use as an optical imaging agent for the det...  \n",
       "11  To treat certain bloodstream infections, bacte...  \n",
       "12  To treat extravascular hemolysis with paroxysm...  \n",
       "13      To treat anemia due to chronic kidney disease  \n",
       "14  To treat pulmonary arterial hypertension\\nDrug...  \n",
       "15  To treat Duchenne muscular dystrophy in indivi...  \n",
       "16        To treat hypertension\\nDrug Trials Snapshot  \n",
       "17  To treat noncirrhotic non-alcoholic steatohepa...  \n",
       "18  To treat unresectable or metastatic esophageal...  \n",
       "19  To temporarily improve the appearance of moder...  \n",
       "20  To treat complicated urinary tract infections\\...  \n",
       "21  To treat molluscum contagiosum\\nDrug Trials Sn...  "
      ],
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Drug Name</th>\n",
       "      <th>Active Ingredient</th>\n",
       "      <th>Approval Date</th>\n",
       "      <th>FDA-approved use on approval date*</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Kisunla</td>\n",
       "      <td>donanemab-azbt</td>\n",
       "      <td>7/2/2024</td>\n",
       "      <td>To treat Alzheimer’s disease</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Ohtuvayre</td>\n",
       "      <td>ensifentrine</td>\n",
       "      <td>6/26/2024</td>\n",
       "      <td>To treat chronic obstructive pulmonary disease</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Piasky</td>\n",
       "      <td>crovalimab-akkz</td>\n",
       "      <td>6/20/2024</td>\n",
       "      <td>To treat paroxysmal nocturnal hemoglobinuria</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Sofdra</td>\n",
       "      <td>sofpironium</td>\n",
       "      <td>6/18/2024</td>\n",
       "      <td>To treat primary axillary hyperhidrosis</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Iqirvo</td>\n",
       "      <td>elafibranor</td>\n",
       "      <td>6/10/2024</td>\n",
       "      <td>To treat primary biliary cholangitis in combin...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Rytelo</td>\n",
       "      <td>imetelstat</td>\n",
       "      <td>6/6/2024</td>\n",
       "      <td>To treat low- to intermediate-1 risk myelodysp...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Imdelltra</td>\n",
       "      <td>tarlatamab-dlle</td>\n",
       "      <td>5/16/2024</td>\n",
       "      <td>To treat extensive stage small cell lung cancer</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Xolremdi</td>\n",
       "      <td>mavorixafor</td>\n",
       "      <td>4/26/2024</td>\n",
       "      <td>To treat WHIM syndrome (warts, hypogammaglobul...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Ojemda</td>\n",
       "      <td>tovorafenib</td>\n",
       "      <td>4/23/2024</td>\n",
       "      <td>To treat relapsed or refractory pediatric low-...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>Anktiva</td>\n",
       "      <td>nogapendekin alfa inbakicept-pmln</td>\n",
       "      <td>4/22/2024</td>\n",
       "      <td>To treat bladder cancer</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>Lumisight</td>\n",
       "      <td>pegulicianine</td>\n",
       "      <td>4/17/2024</td>\n",
       "      <td>To use as an optical imaging agent for the det...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>Zevtera</td>\n",
       "      <td>ceftobiprole medocaril sodium</td>\n",
       "      <td>4/3/2024</td>\n",
       "      <td>To treat certain bloodstream infections, bacte...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>Voydeya</td>\n",
       "      <td>danicopan</td>\n",
       "      <td>3/29/2024</td>\n",
       "      <td>To treat extravascular hemolysis with paroxysm...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>Vafseo</td>\n",
       "      <td>vadadustat</td>\n",
       "      <td>3/27/2024</td>\n",
       "      <td>To treat anemia due to chronic kidney disease</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>Winrevair</td>\n",
       "      <td>sotatercept-csrk</td>\n",
       "      <td>3/26/2024</td>\n",
       "      <td>To treat pulmonary arterial hypertension\\nDrug...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>Duvyzat</td>\n",
       "      <td>givinostat</td>\n",
       "      <td>3/21/2024</td>\n",
       "      <td>To treat Duchenne muscular dystrophy in indivi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>Tryvio</td>\n",
       "      <td>aprocitentan</td>\n",
       "      <td>3/19/2024</td>\n",
       "      <td>To treat hypertension\\nDrug Trials Snapshot</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>Rezdiffra</td>\n",
       "      <td>resmetirom</td>\n",
       "      <td>3/14/2024</td>\n",
       "      <td>To treat noncirrhotic non-alcoholic steatohepa...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>Tevimbra</td>\n",
       "      <td>tislelizumab-jsgr</td>\n",
       "      <td>3/13/2024</td>\n",
       "      <td>To treat unresectable or metastatic esophageal...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>Letybo</td>\n",
       "      <td>letibotulinumtoxinA-wlbg</td>\n",
       "      <td>2/29/2024</td>\n",
       "      <td>To temporarily improve the appearance of moder...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>Exblifep</td>\n",
       "      <td>cefepime, enmetazobactam</td>\n",
       "      <td>2/22/2024</td>\n",
       "      <td>To treat complicated urinary tract infections\\...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>Zelsuvmi</td>\n",
       "      <td>berdazimer</td>\n",
       "      <td>1/5/2024</td>\n",
       "      <td>To treat molluscum contagiosum\\nDrug Trials Sn...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "execution_count": 7
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.7.16"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
